Home ➤ Life Science ➤ Pharmaceuticals ➤ Drug-Resistant Tuberculosis Treatment Market
Drug-Resistant Tuberculosis Treatment Market
Published date: Feb 2024 • Formats:
[email protected] +1 718 874 1545
Request Sample Schedule a Call
Table of Contents

Drug-Resistant Tuberculosis Treatment Market By Drug Class (Amoxicillin/Clavulanate, Bedaquiline, Carbapenems with Clavulanic Acid, Clofazimine, Other Drug Classes) By Disease Type (Active TB, Latent TB) By Treatment Type (First-Line Anti-TB Drugs, Second-Line Anti-TB Drugs) By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

  • Published date: Feb 2024
  • Report ID: 84849
  • Number of Pages: 368
  • Format:
Fact Checked
Drug-Resistant Tuberculosis Treatment Market https://market.us/report/drug-resistant-tuberculosis-treatment-market/
Cite this Research
  • keyboard_arrow_up
    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
      • 1.4. Key Analysis
      • 1.5. Key Findings by Major Segments
      • 1.6. Top strategies by Major Players
    • 2. Global Drug-Resistant Tuberculosis Treatment Overview
      • 2.1. Drug-Resistant Tuberculosis Treatment Dynamics
        • 2.1.1. Drivers
        • 2.1.2. Opportunities
        • 2.1.2. Restraints
        • 2.1.4. Challenges
      • 2.2. Macro-economic Factors
      • 2.3. Regulatory Framework
      • 2.4. Market Investment Feasibility Index
      • 2.5. PEST Analysis
      • 2.6. PORTER’S Five Force Analysis
      • 2.7. Drivers & Restraints Impact Analysis
      • 2.8. Industry Chain Analysis
      • 2.9. Cost Structure Analysis
      • 2.10. Marketing Strategy
      • 2.11. Russia-Ukraine War Impact Analysis
      • 2.12. Opportunity Map Analysis
      • 2.13. Market Competition Scenario Analysis
      • 2.14. Product Life Cycle Analysis
      • 2.15. Opportunity Orbits
      • 2.16. Manufacturer Intensity Map
      • 2.17. Major Companies sales by Value & Volume
    • 3. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
      • 3.1. Global Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
      • 3.2. Global Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
      • 3.3. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
        • 3.3.1. Global Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
        • 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
        • 3.3.3. Amoxicillin/Clavulanate
        • 3.3.4. Bedaquiline
        • 3.3.5. Carbapenems with Clavulanic Acid
        • 3.3.6. Clofazimine
        • 3.3.7. Cycloserine
        • 3.3.8. Delamanid
        • 3.3.9. Ethambutol
        • 3.3.10. Ethionamide and Prothionamide
        • 3.3.11. Other Drug Classes
      • 3.4. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
        • 3.4.1. Global Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
        • 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
        • 3.4.3. Multidrug-Resistant TB (MDR TB)
        • 3.4.4. Extensively Drug-Resistant TB (XDR TB)
      • 3.5. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
        • 3.5.1. Global Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
        • 3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
        • 3.5.3. First-Line Anti-TB Drugs
        • 3.5.4. Second-Line Anti-TB Drugs
        • 3.5.5. Others Treatment Types
      • 3.6. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
        • 3.6.1. Global Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
        • 3.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
        • 3.6.3. Hospital Pharmacies
        • 3.6.4. Online Pharmacies
        • 3.6.5. Retail Pharmacies
        • 3.6.6. Other Distribution Channels
    • 4. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
      • 4.1. North America Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
      • 4.2. North America Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
      • 4.3. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
        • 4.3.1. North America Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
        • 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
        • 4.3.3. Amoxicillin/Clavulanate
        • 4.3.4. Bedaquiline
        • 4.3.5. Carbapenems with Clavulanic Acid
        • 4.3.6. Clofazimine
        • 4.3.7. Cycloserine
        • 4.3.8. Delamanid
        • 4.3.9. Ethambutol
        • 4.3.10. Ethionamide and Prothionamide
        • 4.3.11. Other Drug Classes
      • 4.4. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
        • 4.4.1. North America Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
        • 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
        • 4.4.3. Multidrug-Resistant TB (MDR TB)
        • 4.4.4. Extensively Drug-Resistant TB (XDR TB)
      • 4.5. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
        • 4.5.1. North America Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
        • 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
        • 4.5.3. First-Line Anti-TB Drugs
        • 4.5.4. Second-Line Anti-TB Drugs
        • 4.5.5. Others Treatment Types
      • 4.6. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
        • 4.6.1. North America Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
        • 4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
        • 4.6.3. Hospital Pharmacies
        • 4.6.4. Online Pharmacies
        • 4.6.5. Retail Pharmacies
        • 4.6.6. Other Distribution Channels
      • 4.7. North America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 4.7.1. North America Drug-Resistant Tuberculosis Treatment Analysis by Country : Introduction
        • 4.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 4.7.2.1. U.S.
          • 4.7.2.2. Canada
          • 4.7.2.3. Mexico
    • 5. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
      • 5.1. Europe Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
      • 5.2. Europe Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
      • 5.3. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
        • 5.3.1. Europe Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
        • 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
        • 5.3.3. Amoxicillin/Clavulanate
        • 5.3.4. Bedaquiline
        • 5.3.5. Carbapenems with Clavulanic Acid
        • 5.3.6. Clofazimine
        • 5.3.7. Cycloserine
        • 5.3.8. Delamanid
        • 5.3.9. Ethambutol
        • 5.3.10. Ethionamide and Prothionamide
        • 5.3.11. Other Drug Classes
      • 5.4. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
        • 5.4.1. Europe Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
        • 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
        • 5.4.3. Multidrug-Resistant TB (MDR TB)
        • 5.4.4. Extensively Drug-Resistant TB (XDR TB)
      • 5.5. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
        • 5.5.1. Europe Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
        • 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
        • 5.5.3. First-Line Anti-TB Drugs
        • 5.5.4. Second-Line Anti-TB Drugs
        • 5.5.5. Others Treatment Types
      • 5.6. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
        • 5.6.1. Europe Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
        • 5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
        • 5.6.3. Hospital Pharmacies
        • 5.6.4. Online Pharmacies
        • 5.6.5. Retail Pharmacies
        • 5.6.6. Other Distribution Channels
      • 5.7. Europe Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 5.7.1. Europe Drug-Resistant Tuberculosis Treatment Analysis by Country : Introduction
        • 5.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 5.7.2.1. U.K.
          • 5.7.2.2. Germany
          • 5.7.2.3. France
          • 5.7.2.4. Spain
          • 5.7.2.5. Italy
          • 5.7.2.6. Russia
          • 5.7.2.7. Rest of Europe
    • 6. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
      • 6.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
      • 6.2. Asia-Pacific Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
      • 6.3. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
        • 6.3.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
        • 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
        • 6.3.3. Amoxicillin/Clavulanate
        • 6.3.4. Bedaquiline
        • 6.3.5. Carbapenems with Clavulanic Acid
        • 6.3.6. Clofazimine
        • 6.3.7. Cycloserine
        • 6.3.8. Delamanid
        • 6.3.9. Ethambutol
        • 6.3.10. Ethionamide and Prothionamide
        • 6.3.11. Other Drug Classes
      • 6.4. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
        • 6.4.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
        • 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
        • 6.4.3. Multidrug-Resistant TB (MDR TB)
        • 6.4.4. Extensively Drug-Resistant TB (XDR TB)
      • 6.5. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
        • 6.5.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
        • 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
        • 6.5.3. First-Line Anti-TB Drugs
        • 6.5.4. Second-Line Anti-TB Drugs
        • 6.5.5. Others Treatment Types
      • 6.6. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
        • 6.6.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
        • 6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
        • 6.6.3. Hospital Pharmacies
        • 6.6.4. Online Pharmacies
        • 6.6.5. Retail Pharmacies
        • 6.6.6. Other Distribution Channels
      • 6.7. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 6.7.1. Asia-Pacific Drug-Resistant Tuberculosis Treatment Analysis by Country : Introduction
        • 6.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 6.7.2.1. China
          • 6.7.2.2. Japan
          • 6.7.2.3. South Korea
          • 6.7.2.4. India
          • 6.7.2.5. Rest of Asia-Pacific
    • 7. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
      • 7.1. South America Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
      • 7.2. South America Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
      • 7.3. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
        • 7.3.1. South America Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
        • 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
        • 7.3.3. Amoxicillin/Clavulanate
        • 7.3.4. Bedaquiline
        • 7.3.5. Carbapenems with Clavulanic Acid
        • 7.3.6. Clofazimine
        • 7.3.7. Cycloserine
        • 7.3.8. Delamanid
        • 7.3.9. Ethambutol
        • 7.3.10. Ethionamide and Prothionamide
        • 7.3.11. Other Drug Classes
      • 7.4. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
        • 7.4.1. South America Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
        • 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
        • 7.4.3. Multidrug-Resistant TB (MDR TB)
        • 7.4.4. Extensively Drug-Resistant TB (XDR TB)
      • 7.5. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
        • 7.5.1. South America Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
        • 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
        • 7.5.3. First-Line Anti-TB Drugs
        • 7.5.4. Second-Line Anti-TB Drugs
        • 7.5.5. Others Treatment Types
      • 7.6. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
        • 7.6.1. South America Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
        • 7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
        • 7.6.3. Hospital Pharmacies
        • 7.6.4. Online Pharmacies
        • 7.6.5. Retail Pharmacies
        • 7.6.6. Other Distribution Channels
      • 7.7. South America Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 7.7.1. South America Drug-Resistant Tuberculosis Treatment Analysis by Country : Introduction
        • 7.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 7.7.2.1. Brazil
          • 7.7.2.2. Argentina
          • 7.7.2.3. Rest of South America
    • 8. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, 2016-2032
      • 8.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, 2016-2021
      • 8.2. Middle East and Africa Drug-Resistant Tuberculosis Treatment Opportunity and Forecast, 2023-2032
      • 8.3. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Drug Classes, 2016-2032
        • 8.3.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis by Drug Classes: Introduction
        • 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Classes, 2016-2032
        • 8.3.3. Amoxicillin/Clavulanate
        • 8.3.4. Bedaquiline
        • 8.3.5. Carbapenems with Clavulanic Acid
        • 8.3.6. Clofazimine
        • 8.3.7. Cycloserine
        • 8.3.8. Delamanid
        • 8.3.9. Ethambutol
        • 8.3.10. Ethionamide and Prothionamide
        • 8.3.11. Other Drug Classes
      • 8.4. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Disease Type, 2016-2032
        • 8.4.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis by Disease Type: Introduction
        • 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Disease Type, 2016-2032
        • 8.4.3. Multidrug-Resistant TB (MDR TB)
        • 8.4.4. Extensively Drug-Resistant TB (XDR TB)
      • 8.5. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Treatment Types, 2016-2032
        • 8.5.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis by Treatment Types: Introduction
        • 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment Types, 2016-2032
        • 8.5.3. First-Line Anti-TB Drugs
        • 8.5.4. Second-Line Anti-TB Drugs
        • 8.5.5. Others Treatment Types
      • 8.6. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Distribution Channels, 2016-2032
        • 8.6.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis by Distribution Channels: Introduction
        • 8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Distribution Channels, 2016-2032
        • 8.6.3. Hospital Pharmacies
        • 8.6.4. Online Pharmacies
        • 8.6.5. Retail Pharmacies
        • 8.6.6. Other Distribution Channels
      • 8.7. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 8.7.1. Middle East and Africa Drug-Resistant Tuberculosis Treatment Analysis by Country : Introduction
        • 8.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 8.7.2.1. GCC
          • 8.7.2.2. Israel
          • 8.7.2.3. South Africa
          • 8.7.2.4. Rest of MEA
    • 9. Global Drug-Resistant Tuberculosis Treatment Analysis, Opportunity and Forecast, By Region , 2016-2032
      • 9.1. Global Drug-Resistant Tuberculosis Treatment Analysis by Region : Introduction
      • 9.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
        • 9.2.1. North America
        • 9.2.2. Europe
        • 9.2.3. Asia-Pacific
        • 9.2.4. South America
        • 9.2.5. Middle East and Africa
    • 10. Global Drug-Resistant Tuberculosis Treatment Competitive Landscape, Market Share Analysis, and Company Profiles
      • 10.1. Market Share Analysis
      • 10.2. Company Profiles
      • 10.3. Sanofi SA (France)
        • 10.3.1. Company Overview
        • 10.3.2. Financial Highlights
        • 10.3.3. Product Portfolio
        • 10.3.4. SWOT Analysis
        • 10.3.5. Key Strategies and Developments
      • 10.4. Novartis AG (Switzerland)
        • 10.4.1. Company Overview
        • 10.4.2. Financial Highlights
        • 10.4.3. Product Portfolio
        • 10.4.4. SWOT Analysis
        • 10.4.5. Key Strategies and Developments
      • 10.5. Endo International Plc (Ireland)
        • 10.5.1. Company Overview
        • 10.5.2. Financial Highlights
        • 10.5.3. Product Portfolio
        • 10.5.4. SWOT Analysis
        • 10.5.5. Key Strategies and Developments
      • 10.6. CMP Pharma Inc. ((US$ Mn & Units)ed States)
        • 10.6.1. Company Overview
        • 10.6.2. Financial Highlights
        • 10.6.3. Product Portfolio
        • 10.6.4. SWOT Analysis
        • 10.6.5. Key Strategies and Developments
      • 10.7. STI Pharma LLC ((US$ Mn & Units)ed States)
        • 10.7.1. Company Overview
        • 10.7.2. Financial Highlights
        • 10.7.3. Product Portfolio
        • 10.7.4. SWOT Analysis
        • 10.7.5. Key Strategies and Developments
      • 10.8. Akorn Incorporated ((US$ Mn & Units)ed States)
        • 10.8.1. Company Overview
        • 10.8.2. Financial Highlights
        • 10.8.3. Product Portfolio
        • 10.8.4. SWOT Analysis
        • 10.8.5. Key Strategies and Developments
      • 10.9. Lupin (India)
        • 10.9.1. Company Overview
        • 10.9.2. Financial Highlights
        • 10.9.3. Product Portfolio
        • 10.9.4. SWOT Analysis
        • 10.9.5. Key Strategies and Developments
      • 10.10. Johnson & Johnson Services Inc. ((US$ Mn & Units)ed States)
        • 10.10.1. Company Overview
        • 10.10.2. Financial Highlights
        • 10.10.3. Product Portfolio
        • 10.10.4. SWOT Analysis
        • 10.10.5. Key Strategies and Developments
      • 10.11. Macleods Pharmaceuticals Ltd. (India)
        • 10.11.1. Company Overview
        • 10.11.2. Financial Highlights
        • 10.11.3. Product Portfolio
        • 10.11.4. SWOT Analysis
        • 10.11.5. Key Strategies and Developments
      • 10.12. Pfizer Inc. ((US$ Mn & Units)ed States)
        • 10.12.1. Company Overview
        • 10.12.2. Financial Highlights
        • 10.12.3. Product Portfolio
        • 10.12.4. SWOT Analysis
        • 10.12.5. Key Strategies and Developments
      • 10.13. Hikma Pharmaceuticals PLC ((US$ Mn & Units)ed Kingdom)
        • 10.13.1. Company Overview
        • 10.13.2. Financial Highlights
        • 10.13.3. Product Portfolio
        • 10.13.4. SWOT Analysis
        • 10.13.5. Key Strategies and Developments
      • 10.14. Others.
        • 10.14.1. Company Overview
        • 10.14.2. Financial Highlights
        • 10.14.3. Product Portfolio
        • 10.14.4. SWOT Analysis
        • 10.14.5. Key Strategies and Developments
    • 11. Assumptions and Acronyms
    • 12. Research Methodology
    • 13. Contact

     

    • List of Figures
      • Figure 1: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classes in 2022
      • Figure 2: Global Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
      • Figure 3: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
      • Figure 4: Global Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
      • Figure 5: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
      • Figure 6: Global Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
      • Figure 7: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
      • Figure 8: Global Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
      • Figure 9: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Region in 2022
      • Figure 10: Global Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Region, 2016-2032
      • Figure 11: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Figure 12: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Figure 13: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Figure 14: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Figure 15: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Figure 16: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Figure 17: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Figure 18: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Figure 19: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Figure 20: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Figure 21: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Figure 22: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Region (2016-2032)
      • Figure 23: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Figure 24: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Figure 25: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Figure 26: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
      • Figure 27: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classesin 2022
      • Figure 28: North America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
      • Figure 29: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
      • Figure 30: North America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
      • Figure 31: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
      • Figure 32: North America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
      • Figure 33: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
      • Figure 34: North America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
      • Figure 35: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 36: North America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Country, 2016-2032
      • Figure 37: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Figure 38: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 39: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Figure 40: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Figure 41: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Figure 42: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Figure 43: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 44: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Figure 45: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Figure 46: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Figure 47: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Figure 48: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
      • Figure 49: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Figure 50: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Figure 51: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Figure 52: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
      • Figure 53: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classesin 2022
      • Figure 54: Europe Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
      • Figure 55: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
      • Figure 56: Europe Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
      • Figure 57: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
      • Figure 58: Europe Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
      • Figure 59: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
      • Figure 60: Europe Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
      • Figure 61: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 62: Europe Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Country, 2016-2032
      • Figure 63: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Figure 64: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 65: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Figure 66: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Figure 67: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Figure 68: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Figure 69: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 70: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Figure 71: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Figure 72: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Figure 73: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Figure 74: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
      • Figure 75: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Figure 76: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Figure 77: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Figure 78: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
      • Figure 79: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classesin 2022
      • Figure 80: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
      • Figure 81: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
      • Figure 82: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
      • Figure 83: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
      • Figure 84: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
      • Figure 85: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
      • Figure 86: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
      • Figure 87: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 88: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Country, 2016-2032
      • Figure 89: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Figure 90: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 91: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Figure 92: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Figure 93: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Figure 94: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Figure 95: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 96: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Figure 97: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Figure 98: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Figure 99: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Figure 100: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
      • Figure 101: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Figure 102: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Figure 103: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Figure 104: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
      • Figure 105: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classesin 2022
      • Figure 106: South America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
      • Figure 107: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
      • Figure 108: South America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
      • Figure 109: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
      • Figure 110: South America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
      • Figure 111: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
      • Figure 112: South America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
      • Figure 113: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 114: South America Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Country, 2016-2032
      • Figure 115: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Figure 116: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 117: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Figure 118: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Figure 119: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Figure 120: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Figure 121: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 122: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Figure 123: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Figure 124: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Figure 125: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Figure 126: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
      • Figure 127: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Figure 128: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Figure 129: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Figure 130: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
      • Figure 131: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Drug Classesin 2022
      • Figure 132: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Drug Classes, 2016-2032
      • Figure 133: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Disease Typein 2022
      • Figure 134: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Disease Type, 2016-2032
      • Figure 135: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Treatment Typesin 2022
      • Figure 136: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Treatment Types, 2016-2032
      • Figure 137: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Distribution Channelsin 2022
      • Figure 138: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Distribution Channels, 2016-2032
      • Figure 139: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 140: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Attractiveness Analysis by Country, 2016-2032
      • Figure 141: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Figure 142: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 143: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Figure 144: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Figure 145: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Figure 146: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Figure 147: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 148: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Figure 149: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Figure 150: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Figure 151: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Figure 152: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
      • Figure 153: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Figure 154: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Figure 155: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Figure 156: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)

       

    • List of Tables
      • Table 1: Global Drug-Resistant Tuberculosis Treatment Market Comparison by Drug Classes (2016-2032)
      • Table 2: Global Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
      • Table 3: Global Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
      • Table 4: Global Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
      • Table 5: Global Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 6: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Table 7: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 8: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Table 9: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Table 10: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Table 11: Global Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Table 12: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Table 13: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Table 14: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Table 15: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Table 16: Global Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Table 17: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Region (2016-2032)
      • Table 18: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Table 19: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Table 20: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Table 21: Global Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
      • Table 22: North America Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
      • Table 23: North America Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
      • Table 24: North America Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
      • Table 25: North America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 26: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Table 27: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 28: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Table 29: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Table 30: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Table 31: North America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Table 32: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 33: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Table 34: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Table 35: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Table 36: North America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Table 37: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
      • Table 38: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Table 39: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Table 40: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Table 41: North America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
      • Table 42: Europe Drug-Resistant Tuberculosis Treatment Market Comparison by Drug Classes (2016-2032)
      • Table 43: Europe Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
      • Table 44: Europe Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
      • Table 45: Europe Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
      • Table 46: Europe Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 47: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Table 48: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 49: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Table 50: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Table 51: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Table 52: Europe Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Table 53: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 54: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Table 55: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Table 56: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Table 57: Europe Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Table 58: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
      • Table 59: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Table 60: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Table 61: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Table 62: Europe Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
      • Table 63: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Comparison by Drug Classes (2016-2032)
      • Table 64: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
      • Table 65: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
      • Table 66: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
      • Table 67: Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 68: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Table 69: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 70: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Table 71: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Table 72: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Table 73: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Table 74: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 75: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Table 76: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Table 77: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Table 78: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Table 79: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
      • Table 80: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Table 81: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Table 82: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Table 83: Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
      • Table 84: South America Drug-Resistant Tuberculosis Treatment Market Comparison by Drug Classes (2016-2032)
      • Table 85: South America Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
      • Table 86: South America Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
      • Table 87: South America Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
      • Table 88: South America Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 89: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Table 90: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 91: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Table 92: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Table 93: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Table 94: South America Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Table 95: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 96: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Table 97: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Table 98: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Table 99: South America Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Table 100: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
      • Table 101: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Table 102: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Table 103: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Table 104: South America Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
      • Table 105: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Comparison by Drug Classes (2016-2032)
      • Table 106: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Comparison by Disease Type (2016-2032)
      • Table 107: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Comparison by Treatment Types (2016-2032)
      • Table 108: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Comparison by Distribution Channels (2016-2032)
      • Table 109: Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 110: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) (2016-2032)
      • Table 111: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 112: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Drug Classes (2016-2032)
      • Table 113: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Disease Type (2016-2032)
      • Table 114: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Treatment Types (2016-2032)
      • Table 115: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Revenue (US$ Mn) Comparison by Distribution Channels (2016-2032)
      • Table 116: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 117: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Drug Classes (2016-2032)
      • Table 118: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Disease Type (2016-2032)
      • Table 119: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Treatment Types (2016-2032)
      • Table 120: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Y-o-Y Growth Rate Comparison by Distribution Channels (2016-2032)
      • Table 121: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Country (2016-2032)
      • Table 122: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Drug Classes (2016-2032)
      • Table 123: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Disease Type (2016-2032)
      • Table 124: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Treatment Types (2016-2032)
      • Table 125: Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Share Comparison by Distribution Channels (2016-2032)
    • Sanofi SA
    • Novartis AG
    • Endo International Plc
    • CMP Pharma Inc.
    • STI Pharma LLC
    • Akorn Incorporated
    • Lupin
    • Johnson & Johnson Services Inc.
    • Macleods Pharmaceuticals Ltd.
    • Pfizer Inc.
    • Hikma Pharmaceuticals PLC
Drug-Resistant Tuberculosis Treatment Market
Drug-Resistant Tuberculosis Treatment Market
Published date: Feb 2024
add_shopping_cartBuy Now get_appDownload Sample

Related Reports

Drug-Resistant Tuberculosis Treatment Market
  • 84849
  • Feb 2024
    • ★★★★★
      ★★★★★
Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo
  • Client Logo

Our Clients

✖
Request a Sample Report
We'll get back to you as quickly as possible

✖
Request a Sample Report
We'll get back to you as quickly as possible

Find Help
Legal
Explore
Secured Payment Options
Secured Payment Options